• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Scholar Rock Holding Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant

    6/3/25 4:02:04 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SRRK alert in real time by email
    0001727196false00017271962025-06-032025-06-03

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    ​

    FORM 8-K

    ​

    ​

    CURRENT REPORT

    ​

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    ​

    Date of Report (Date of earliest event Reported): June 3, 2025

    ​

    Scholar Rock Holding Corporation

    (Exact Name of Registrant as Specified in Charter)

    ​

    ​

    ​

    ​

    ​

    ​

    Delaware

        

    001-38501

        

    82-3750435

    (State or Other Jurisdiction of
    Incorporation)

    ​

    (Commission File Number)

    ​

    (I.R.S. Employer Identification Number)

    ​

    301 Binney Street, 3rd Floor, Cambridge, MA 02142

    (Address of Principal Executive Offices) (Zip Code)

    ​

    (857) 259-3860

    (Registrant’s telephone number, including area code)

    ​

    (Former name or former address, if changed since last report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ​

    ​

    ​

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ​

    ​

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ​

    ​

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ​

    ​

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered

    Common Stock, par value $0.001 per share

    SRRK

    The Nasdaq Global Select Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    ​

    Item 4.01. Changes in Registrant’s Certifying Accountant.

     

    (b) Engagement of New Independent Registered Public Accounting Firm

     

    On June 3, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of Scholar Rock Holding Corporation (the “Company”) appointed Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The Audit Committee conducted a competitive process in which multiple firms were invited to participate to select a firm to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

    During the fiscal years ended December 31, 2024 and 2023 and the subsequent interim period through June 3, 2025, neither the Company nor anyone on its behalf consulted with Deloitte with respect to (a) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s consolidated financial statements, and neither a written report nor oral advice was provided to the Company that Deloitte concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (b) any matter that was either the subject of a “disagreement” (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto) or a “reportable event” (as described in Item 304(a)(1)(v) of Regulation S-K).

    ​

    ​

    ​

    ​

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Scholar Rock Holding Corporation

     

     

     

    Date: June 3, 2025

    By:

    /s/ Junlin Ho

     

     

    Junlin Ho

     

     

    General Counsel & Corporate Secretary

    ​

    ​

    ​

    Get the next $SRRK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRRK

    DatePrice TargetRatingAnalyst
    11/26/2024$40.00 → $50.00Buy
    H.C. Wainwright
    10/7/2024$30.00 → $35.00Buy
    H.C. Wainwright
    3/28/2024$30.00Strong Buy
    Raymond James
    10/25/2023$20.00Hold → Buy
    Jefferies
    4/3/2023$26.00Overweight
    Piper Sandler
    9/19/2022$30.00Buy
    H.C. Wainwright
    7/12/2022$20.00Buy
    Truist
    3/23/2022$24.00Buy
    H.C. Wainwright
    More analyst ratings

    $SRRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

      SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

      11/14/24 9:00:58 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

      SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

      11/14/24 7:24:55 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

      SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

      11/14/24 1:22:38 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    SEC Filings

    See more
    • SEC Form 144 filed by Scholar Rock Holding Corporation

      144 - Scholar Rock Holding Corp (0001727196) (Subject)

      6/5/25 4:57:15 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock Holding Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant

      8-K - Scholar Rock Holding Corp (0001727196) (Filer)

      6/3/25 4:02:04 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Scholar Rock Holding Corporation

      144 - Scholar Rock Holding Corp (0001727196) (Subject)

      5/29/25 4:51:49 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Flier Jeffrey S. sold $180,584 worth of shares (6,075 units at $29.73), decreasing direct ownership by 20% to 24,070 units (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      5/30/25 4:32:03 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Burow Kristina sold $160,511 worth of shares (5,400 units at $29.72), decreasing direct ownership by 20% to 21,071 units (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      5/30/25 4:31:54 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Gilman Michael sold $100,304 worth of shares (3,375 units at $29.72), decreasing direct ownership by 6% to 55,216 units (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      5/30/25 4:31:44 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

      Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that David L. Hallal, Chief Executive Officer, and members of management will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 11 at 9:20 a.m. ET in Miami, Florida. A live webcast of the events may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. Archived replays of the webcasts will be available on the Company's websit

      6/5/25 8:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager

      Rebecca McLeod brings exceptional U.S. operating experience; most recently served as argenx U.S. General Manager responsible for leading the launch of VYVGART® for gMG and CIDP Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that Rebecca McLeod has been appointed to the newly created role of Chief Brand Officer and U.S. General Manager. In this role, she will be responsible for leading the anticipated U.S. commercial launch of apitegromab for patients with SMA – along with establishing the globa

      6/2/25 8:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock to Present at the Jefferies Global Healthcare Conference

      Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that David L. Hallal, Chief Executive Officer, and members of the management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4 at 3:45 p.m. ET in New York City. A live webcast of the events may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. Archived replays of the webcasts will be available on the Company's website for app

      5/28/25 8:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Financials

    Live finance-specific insights

    See more
    • Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

      Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that David L. Hallal, Chief Executive Officer, and members of management will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 11 at 9:20 a.m. ET in Miami, Florida. A live webcast of the events may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. Archived replays of the webcasts will be available on the Company's websit

      6/5/25 8:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager

      Rebecca McLeod brings exceptional U.S. operating experience; most recently served as argenx U.S. General Manager responsible for leading the launch of VYVGART® for gMG and CIDP Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that Rebecca McLeod has been appointed to the newly created role of Chief Brand Officer and U.S. General Manager. In this role, she will be responsible for leading the anticipated U.S. commercial launch of apitegromab for patients with SMA – along with establishing the globa

      6/2/25 8:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock to Present at the Jefferies Global Healthcare Conference

      Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that David L. Hallal, Chief Executive Officer, and members of the management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4 at 3:45 p.m. ET in New York City. A live webcast of the events may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. Archived replays of the webcasts will be available on the Company's website for app

      5/28/25 8:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Akkaraju Srinivas bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      10/18/23 5:46:02 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Samsara Biocapital Gp, Llc bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      10/18/23 5:44:33 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invus Public Equities, L.P. bought $15,086,736 worth of shares (2,199,931 units at $6.86) (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      10/16/23 5:46:56 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Leadership Updates

    Live Leadership Updates

    See more
    • Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer

      - Former Vice President and Global HR Head of Oncology and Pharma Development at Novartis brings extensive leadership experience focused on talent, culture, and diversity Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer. She will join the executive team, bringing more than 20 years of experience as a senior leader and strategic executive in the biotechnology and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.co

      8/16/21 4:05:00 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright reiterated coverage on Scholar Rock with a new price target

      H.C. Wainwright reiterated coverage of Scholar Rock with a rating of Buy and set a new price target of $50.00 from $40.00 previously

      11/26/24 8:04:27 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright reiterated coverage on Scholar Rock with a new price target

      H.C. Wainwright reiterated coverage of Scholar Rock with a rating of Buy and set a new price target of $35.00 from $30.00 previously

      10/7/24 9:45:10 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James initiated coverage on Scholar Rock with a new price target

      Raymond James initiated coverage of Scholar Rock with a rating of Strong Buy and set a new price target of $30.00

      3/28/24 7:48:04 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care